Due to an Editorial Office error, the following declaration was missed from the Conflict of Interest statement: “The handling editor NJ declared a past collaboration with the author EM.”
The publisher apologizes for this mistake. The original version of this article has been updated.
Summary
Keywords
PAMAM dendrimer, congestive heart failure, solubility enhancement, sustained release, biocompatibility
Citation
Frontiers Production Office (2023) Erratum: Development of a quaternary ammonium poly (amidoamine) dendrimer-based drug carrier for the solubility enhancement and sustained release of furosemide. Front. Chem. 11:1236207. doi: 10.3389/fchem.2023.1236207
Received
07 June 2023
Accepted
07 June 2023
Published
13 June 2023
Approved by
Frontiers Editorial Office, Frontiers Media SA, Switzerland
Volume
11 - 2023
Updates
Copyright
© 2023 Frontiers Production Office.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Frontiers Production Office, production.office@frontiersin.org
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.